<DOC>
	<DOCNO>NCT02581631</DOCNO>
	<brief_summary>This signal study ass whether nivolumab combination brentuximab vedotin safe effective certain subtypes non-hodgkin lymphoma .</brief_summary>
	<brief_title>A Safety Effectiveness Study Nivolumab Combination With Brentuximab Vedotin Treat Non-Hodgkin Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Relapsed/refractory diffuse large B cell lymphoma ( DLBCL ) , relapsed/refractory peripheral T cell lymphoma ( PTCL ) ( subtypes exclude anaplastic large cell lymphoma ) , relapsed/refractory Cutaneous T cell lymphoma ( CTCL ) mycosis fungoides/sezary syndrome ( MF/SS ) , relapsed/refractory primary mediastinal B lymphoma ( PMBL ) , relapsed/refractory mediastinal gray zone lymphoma ( MGZL ) Expression CD30 Subjects must 18 year old ( â‰¥ 15 year PMBL ) Known central nervous system ( CNS ) lymphoma ; Active cerebral/meningeal disease relate underlying malignancy Active , know , suspect autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>